Special Report: EZZ Life Science Holdings is counting on a rebound in Chinese tourist numbers to increase sales of its premium genomic health products and has reached agreements with duty-free retailers to achieve this objective. The company produces a range of health supplements, health food, haircare, children’s health and probiotics under the brand EZZ. EZZ …
Jon Bird, Contributor I’m a retail passionate who lives in Sydney, Australia but covers the world. As many people who have swiped right can tell you, it’s one thing to view a profile online, quite another to spend time with someone In Real Life. So, last week over 30 major buyers and distributors from China …
Read more “Aussie Brands ‘Speed Dating’ And Live Streaming To Success With Alibaba”
Special Report: Genomic life science company EZZ Life Science has struck an advertising partnership deal with the Asia Pacific Aviator Club (APAC), which will see EZZ and EAORON branding across 2 million boarding passes. EZZ Life Science (ASX: EZZ) says under the partnership, set to go live by the end of March, EZZ and EAORON …
Read more “Up and away – EZZ partners with Asia Pacific Aviator Club”
By NADINE MCGRATH STOCKHEAD9:16AM OCTOBER 25, 2023 China has a deep-rooted history in traditional wellness practices and products. And the West has adopted a significant portion of its wellness culture from the East and particularly China, from its unique medicines to tai chi. However, things are now going the other way, with China adopting many …
EZZ Life Science (ASX:EZZ) will see its skincare and health supplement range meet a wider audience, selling its products on the online marketplace of Australia’s largest retail pharmacy Chemist Warehouse. EZZ is working to become a top life science company in Australia and New Zealand. Its core focus has been on genomic health and developing …
Read more “EZZ Life Science is selling its products on Chemist Warehouse’s new online marketplace”
Director of Corporate Affairs, EZZ Life Science Holdings
James Hudson is the Director of Corporate Affairs at EZZ Life Science, where he oversees media relations, investor relations, and public affairs for the company.
Before joining EZZ, James was the Director of Corporate Affairs and Marketing at Alibaba Group for Australia and New Zealand. He has also served as the CEO of the Australia China Business Council's NSW branch, where he supported member companies in trade, investment, and business engagements with China. Additionally, he has held the role of China and East Asia Adviser at CSIRO, Australia’s national science research agency.
James has been appointed to various Advisory Board and Ambassador positions, including with the Asia Education Foundation, the China Australia Millennial Project, AsiaRecon, the Asian Football Cup, and Austrade’s Approved Destination Status Advisory Panel. He has also served as a non-executive director for organisations such as OneSky Australia and the Castlemaine State Festival.
Company Secretary
Jay Stephenson has been involved in business development for over 35 years including approximately 29 years as Director, Chief Financial Officer and Company Secretary for various listed and unlisted entities in resources, manufacturing, information technology, health care, wine, hotels and property. Jay has been involved in business acquisitions, mergers, initial public offerings, capital raisings, business restructuring as well managing all areas of finance for companies.
Jay provides services in IPO/RTO management, Corporate Advisory, Company Administration, Accounting and Corporate Governance. On most engagements, Jay takes on the appointment of a statutory office holder, either as a Director, Company Secretary or Chief Financial Officer.
Jay holds a Master of Business Administration, is a Chartered Accountant, Fellow of Certified Practicing Accountants Australia, A Fellow of the Governance Institute of Australia, a member of Chartered Professional Accountants and Certified Management Accountants in Canada.
Chief Financial Officer
With over 30 years of experience as a chartered accountant, Anthony Guarna has held positions at Deloitte, BDO, and Nexia, both domestically and internationally. He has provided financial leadership at organizations such as Energy Australia, the University of Sydney, Macquarie University, Tower Life, Electroboard Group, the Australian Institute of Higher Education, Austral Gold Limited (ASX: AGD), Aumake Limited (ASX: AUK), and Freedom Insurance Group Limited (ASX: FIG). Anthony also serves as a Non-Executive Director of the Sydney Institute of Traditional Chinese Medicine and is a member of the Advisory Board at Medigalaxy.
Independent Non-Executive Director
With more than 20 years in senior management within the banking industry, Lily Huang serves as Vice President in the investment partnerships division at Citi Group Australia. Her leadership was recognized in 2015 when she was named among the Top 10 Australian Chinese Entrepreneurs.
Independent Non-Executive Director
Bringing over 30 years of legal practice experience both in Australia and internationally, Ivan Oshry specializes in corporate law. He has advised on numerous IPO transactions globally and is a sought-after speaker at various conferences, reflecting his deep industry knowledge.
Executive Director and Chief Executive Officer
An award-winning research analyst and accomplished entrepreneur, Mark Qin co-founded CE International, a multi-award-winning marketing consulting firm. Between 2003 and 2008, he authored five books on sales and marketing within the healthcare industry, showcasing his dedication to advancing the sector.
Independent Non-Executive Director and Chairman
With four decades in the life sciences sector, Glenn Cross has held senior executive roles across multinational and Australian companies. His expertise spans general management, sales, marketing, finance, distribution, and manufacturing. Notably, Glenn served as Chief Operating Officer and CEO of AusBiotech for over 13 years. Currently, he contributes as a non-executive director to various private and public companies, as well as investment funds.